Romiplostim N01 for Chemotherapy-induced Thrombocytopenia
Status:
RECRUITING
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of Romiplostim N01 to treat chemotherapy-induced thrombocytopenia in tumors
Phase:
PHASE2
Details
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China
Collaborators:
Henan Cancer Hospital The Second Affiliated Hospital of Kunming Medical University Tianjin Medical University Cancer Institute and Hospital Tianjin Medical University Second Hospital Tianjin People's Hospital Tianjin Third Central Hospital